Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Raymond James & Associates

Raymond James & Associates boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 8.5% in the first quarter, Holdings Channel.com reports. The firm owned 1,775,106 shares of the medical research company’s stock after acquiring an additional 139,515 shares during the quarter. Raymond James & Associates’ holdings in Edwards Lifesciences were worth $169,629,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of EW. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $34,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences during the first quarter worth about $34,000. Pingora Partners LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $38,000. Finally, Operose Advisors LLC grew its stake in shares of Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after buying an additional 452 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares in the company, valued at approximately $2,980,774.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 194,004 shares of company stock worth $17,166,254. 1.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday. Mizuho lifted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday. Stifel Nicolaus lifted their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $92.71.

Edwards Lifesciences Stock Performance

EW stock traded down $0.48 during midday trading on Monday, reaching $85.95. The company had a trading volume of 2,931,204 shares, compared to its average volume of 3,839,852. The firm has a market capitalization of $51.74 billion, a PE ratio of 37.05, a P/E/G ratio of 4.28 and a beta of 1.05. The stock has a 50 day moving average price of $90.27 and a 200 day moving average price of $79.06. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.